A liquid biopsy is a diagnostic test using liquid biological samples. Considered non-invasive, it can be used to track cancers, heart issues, and do prenatal diagnosis.
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
The versatility of standard PCR and qPCR is well known. Digital PCR is now taking this to a whole new level. The power of partitioning enables you to explore new frontiers which have been li...
DATE: April 15, 2020 TIME: 9:00am PT, 12:00pm ET We report a molecular assay, Methyl-HiC, that can simultaneously capture the chromosome conformation and DNA methylome in a cell. Methyl-HiC...
DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Oncologists have many options when tasked with treating a patient’s cancer. Unfortunately, many cancer drugs and therapies come with potentially debilitating side effects. As such, it i...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
In the past years, next-generation sequencing has revolutionized the way testing is done in the field of clinical oncology research. Parallel testing of genomic markers in tissue biopsies as...
The versatility of standard PCR and qPCR is well known. Digital PCR is now taking this to a whole new level. The power of partitioning enables you to explore new frontiers which have been li...
DATE: April 15, 2020 TIME: 9:00am PT, 12:00pm ET We report a molecular assay, Methyl-HiC, that can simultaneously capture the chromosome conformation and DNA methylome in a cell. Methyl-HiC...
DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Oncologists have many options when tasked with treating a patient’s cancer. Unfortunately, many cancer drugs and therapies come with potentially debilitating side effects. As such, it i...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
Follow
